Buparlisib | Jotup

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

Retrieved on:

Monday, October 23, 2023

ESMO, Health, SCCHN, Head, Poster, Paclitaxel, Partnership, H&E, Digital pathology, ANL, CMO, NORTH, Patient, Medical imaging, Buparlisib

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology company focused on innovative oncology drugs, and Nucleai, a pathology-based AI-powered biomarker discovery and diagnostics company, is pleased to announce today the receipt of the ESMO 2023 Best Poster Award for the Sunday, October 22, 2023 poster session with the presentation of the study “Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN”.

Key Points:

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology company focused on innovative oncology drugs, and Nucleai, a pathology-based AI-powered biomarker discovery and diagnostics company, is pleased to announce today the receipt of the ESMO 2023 Best Poster Award for the Sunday, October 22, 2023 poster session with the presentation of the study “Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN”.
We are extremely pleased the study was recognized for its quality and success,” said Dr. Lars Birgerson, President & CMO of Adlai Nortye.
The poster, #869P, was presented at the Head and Neck Cancers poster session on Sunday, October 22, 2023.
The Best Poster Award was given at the conclusion of the Sunday Poster Session.

PD-1 Resistant Head and Neck Cancer (HNC) Market Insights, Epidemiology and Forecast 2030: Focus on Germany, France, Italy, Spain, United Kingdom, Japan, China, South Korea, and Taiwan - ResearchAndMarkets.com

Retrieved on:

Monday, August 30, 2021

The "PD-1 Resistant Head and Neck Cancer (HNC) - Market Insight, Epidemiology and Market Forecast 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "PD-1 Resistant Head and Neck Cancer (HNC) - Market Insight, Epidemiology and Market Forecast 2030" report has been added to ResearchAndMarkets.com's offering.
The report also covers current PD-1 Resistant Head and Neck Cancer symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities.
The epidemiology segment also provides the PD-1 Resistant Head and Neck Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, South Korea, and Taiwan.
The PD-1 Resistant Head and Neck Cancer report's drug chapter segment encloses the detailed analysis of PD-1 Resistant Head and Neck Cancer's early-stage (Phase I, II, and III) pipeline drugs.

Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer

Retrieved on:

Monday, March 8, 2021

Oncology, Health, Consumer, Women, Clinical trials, Pharmaceutical, Biotechnology, Health sciences, Health, Breast cancer, Medicine, Clinical trial, Iniparib, Buparlisib, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc.

Dr. Thompson commented, I am excited to begin managing our Phase III clinical trial for recurring breast cancer.

Key Points:

Dr. Thompson commented, I am excited to begin managing our Phase III clinical trial for recurring breast cancer.
Over 3 million U.S. breast cancer survivors need safe and effective drugs to prevent metastatic breast cancer recurrence.
I look forward to leveraging my prior experiences in protocol and trial design, clinical trial start-up activities, clinical trial management, statistical analysis of clinical and biomarker data, and management of relationships with U.S. and European regulators as we commence the GP2 Phase III trial.
Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.

Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Cancer

Retrieved on:

Tuesday, June 23, 2020

Clinical medicine, Medicine, Cancer, Quinazolines, Cancer treatments, Lung cancer, HER2/neu, Non-small-cell lung carcinoma, Breast cancer, Interstitial lung disease, Tucatinib, Buparlisib

"Our latest partnership with Daiichi Sankyo is focused on helping to solve an unmet medical need for a growing number of patients with HER2-mutated non-small cell lung cancer," said Garret Hampton, president of clinical next-generation sequencing and oncology at Thermo Fisher Scientific.

Key Points:

"Our latest partnership with Daiichi Sankyo is focused on helping to solve an unmet medical need for a growing number of patients with HER2-mutated non-small cell lung cancer," said Garret Hampton, president of clinical next-generation sequencing and oncology at Thermo Fisher Scientific.
Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU.
In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer treated with ENHERTU, ILD occurred in 9% of patients.
3 Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting; Jean-Bernard Auliac, et al.

KEYTRUDA's Recent Success in Triple-Negative Breast Cancer Validates I-SPY 2 Adaptive Platform Approach to Phase II Clinical Trials

Retrieved on:

Wednesday, August 7, 2019

Health, Clinical research, Medical research, Drug discovery, Pharmaceutical industry, Food and Drug Administration, Clinical trial, Design of experiments, Triple-negative breast cancer, Drug development, Investigational New Drug, Buparlisib

The KEYNOTE-522 pCR results offer promise for triple negative breast cancer patients who need better treatment options."

Key Points:

The KEYNOTE-522 pCR results offer promise for triple negative breast cancer patients who need better treatment options."
The I-SPY 2 trial is considered the archetype of a new approach to clinical trials.
Rather than the traditional 'one drug, one disease' model for drug development, it is a 'platform' trial.
In this approach, the results of each patient are used to refine how the investigational drugs are assigned to new patients.

OncLive® Presents State of the Science Summit™ on Breast Cancer

Retrieved on:

Wednesday, June 19, 2019

Practice Management, Health, Oncology, Other Health, Other Science, Science, Medicine, Clinical medicine, Breast cancer, Health, RTT, HER2/neu, Triple-negative breast cancer, CDK inhibitor, Buparlisib

The summit will be chaired by Dr. Lisa Newman, chief of the section of breast surgery at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine.

Key Points:

The summit will be chaired by Dr. Lisa Newman, chief of the section of breast surgery at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine.
This interactive and educational meeting will discuss novel treatments for patients with breast cancer.
Expert presenters will delve into informative topics facing breast cancer specialists, oncologists, nurses and other medical professionals, such as management of HR-positive/HER2-negative, estrogen receptor-positive disease; metastatic HR-positive/HER2-negative disease; genetics of breast cancer disparities and triple-negative breast cancer related to African ancestry; role of radiation in early breast cancer; HER2-positive breast cancer; and metastatic triple-negative breast cancer.
Combining science and humanity to make cancer understandable, CURE reaches patients, cancer centers and advocacy groups.